FDA Clears ThinkSono’s Ultrasound AI Guidance Software to Evaluate Suspected DVT

July 29, 2026—ThinkSono announced that the company’s ThinkSono Guidance software has received FDA 510(k) clearance that provides real-time guidance to nonultrasound-trained health care professionals during the acquisition of vascular ultrasound images.

SAT’s FDA-Cleared CenterFlow Post-TEVAR Molding Catheter Used in FIH Procedures

July 29, 2026—Strait Access Technologies (SAT), which is based in Cape Town, South Africa, announced the first-in-human use of its CenterFlow post-thoracic endovascular aneurysm repair (TEVAR) stent graft balloon molding catheter.

Magnendo Raises Financing for Development of Magnetic Robotic Navigation System for Neuro-Endovascular Intervention

July 29, 2026—Magnendo Corp.

Fluidx Submits Final PMA Module to FDA for GPX Embolic Device

July 24, 2026—Fluidx Medical Technology, Inc. announced that the final module of its premarket approval (PMA) application for the company’s GPX embolic device has been submitted to the FDA.

Enrollment Completed in INSYTE Trial of Spryte’s nOCT Imaging System

July 23, 2026—Spryte Medical announced the completion of patient enrollment of the INSYTE trial of the company’s investigational neuro OCT (nOCT) imaging system.

THUNDER Results Presented for Penumbra’s Thunderbolt CAVT System in Stroke Patients

July 22, 2026—Penumbra, Inc. announced the results of the THUNDER investigational device exemption (IDE) study evaluating the safety and effectiveness of the company’s Thunderbolt computer assisted vacuum thrombectomy (CAVT) system in stroke patients with emergent large vessel occlusion (ELVO). The single-arm, prospective, multicenter study used core-lab adjudication and enrolled 216 patients across 29 centers in the United States.

Fujifilm Sonosite Launches iLook Ultrasound Solution for Vascular Access

July 22, 2026—Fujifilm Sonosite, Inc., a developer of point-of-care ultrasound (POCUS) solutions, announced the launch of Sonosite iLook, its compact ultrasound solution designed specifically for vascular access.

EMBO-02 FIH Study of Arsenal’s NeoCast Liquid Embolic Meets Endpoints in Treatment of cSDH

July 22, 2026—Arsenal Medical announced late-breaking results from the EMBO-02 first-in-human (FIH) clinical study, which is evaluating the company’s NeoCast liquid embolic for middle meningeal artery embolization (MMAe) to treat chronic subdural hematoma (cSDH).